Every S-3 that Co-Diagnostics, Inc. (CODX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow CODX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CODX filings page.
Co-Diagnostics, Inc. (CODX) is registering the resale of up to 3,404,724 shares of common stock for selling stockholders. These shares are issuable upon exercise of “New Warrants” issued under a July 30, 2026 Inducement Letter. CODX will not receive proceeds from the selling stockholders’ resales.
If all New Warrants are exercised for cash at $1.56 per share, CODX could receive up to approximately $5.31 million, planned for working capital and general corporate purposes; the warrants are also exercisable on a cashless basis, in which case the company would receive no cash. Common shares outstanding were 6,981,319 as of August 20, 2026, or 10,386,043 assuming full exercise of the New Warrants.
CODX develops and sells PCR-based molecular diagnostics, including tests for COVID‑19 and other infectious diseases, and is pursuing U.S. FDA clearance for its Co-Dx PCR platform. The company highlights dilution and stock overhang risks from warrant exercises and future equity issuances, and notes Nasdaq listing under the symbol CODX.
Co-Diagnostics, Inc. filed a registration statement to permit resale by selling stockholders of up to 4,942,341 shares of its common stock, comprised of 54,915 PIPE Shares, 1,592,532 Pre-Funded Warrant Shares and 3,294,894 Common Warrant Shares. The selling holders acquired the securities in a private placement on May 21, 2026. The Company will not receive proceeds from resales, but could receive up to approximately $5.18 million if the Warrants are exercised for cash. Shares outstanding were 3,685,314 as of May 27, 2026. The registration permits the selling stockholders to dispose of shares under various sale methods described in the Plan of Distribution.
Co-Diagnostics, Inc. registered a shelf to offer up to $150,000,000 of securities from time to time, including common stock, preferred stock, debt securities, warrants, units and rights.
The prospectus states each offering will be described in a separate prospectus supplement and that net proceeds are intended for working capital and general corporate purposes, with possible uses including product development, sales and marketing expansion, acquisitions and debt repayment.